1. Home
  2. IMRX vs SPRO Comparison

IMRX vs SPRO Comparison

Compare IMRX & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMRX
  • SPRO
  • Stock Information
  • Founded
  • IMRX 2008
  • SPRO 2013
  • Country
  • IMRX United States
  • SPRO United States
  • Employees
  • IMRX N/A
  • SPRO N/A
  • Industry
  • IMRX Biotechnology: Pharmaceutical Preparations
  • SPRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMRX Health Care
  • SPRO Health Care
  • Exchange
  • IMRX Nasdaq
  • SPRO Nasdaq
  • Market Cap
  • IMRX 73.2M
  • SPRO 63.0M
  • IPO Year
  • IMRX 2021
  • SPRO 2017
  • Fundamental
  • Price
  • IMRX $1.78
  • SPRO $1.05
  • Analyst Decision
  • IMRX Buy
  • SPRO Buy
  • Analyst Count
  • IMRX 7
  • SPRO 3
  • Target Price
  • IMRX $12.80
  • SPRO $5.00
  • AVG Volume (30 Days)
  • IMRX 801.9K
  • SPRO 205.6K
  • Earning Date
  • IMRX 11-13-2024
  • SPRO 11-14-2024
  • Dividend Yield
  • IMRX N/A
  • SPRO N/A
  • EPS Growth
  • IMRX N/A
  • SPRO N/A
  • EPS
  • IMRX N/A
  • SPRO 0.06
  • Revenue
  • IMRX N/A
  • SPRO $106,455,000.00
  • Revenue This Year
  • IMRX N/A
  • SPRO N/A
  • Revenue Next Year
  • IMRX N/A
  • SPRO N/A
  • P/E Ratio
  • IMRX N/A
  • SPRO $16.37
  • Revenue Growth
  • IMRX N/A
  • SPRO 37.01
  • 52 Week Low
  • IMRX $1.00
  • SPRO $1.01
  • 52 Week High
  • IMRX $8.07
  • SPRO $1.89
  • Technical
  • Relative Strength Index (RSI)
  • IMRX 37.40
  • SPRO 31.12
  • Support Level
  • IMRX $1.52
  • SPRO $1.12
  • Resistance Level
  • IMRX $1.93
  • SPRO $1.20
  • Average True Range (ATR)
  • IMRX 0.19
  • SPRO 0.04
  • MACD
  • IMRX -0.05
  • SPRO -0.01
  • Stochastic Oscillator
  • IMRX 21.95
  • SPRO 13.67

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: